A Phase 1/2 interventional study of Ibrutinib and Lenalidomide in Relapsed Diffuse Large B-Cell Lymphoma and Refractory Diffuse Large B-Cell Lymphoma, sponsored by Pharmacyclics LLC.. Completed at 40 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-04.
Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse — 3 open to participants now, 10 under way, 2 of them phase 3. ibrutinib · Lymphoma, Large B-Cell, Diffuse.
Among the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 5th largest by enrollment, is one of 4 that started in 2014, is one of 6 in phase 1/2, and was the 6th registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →3 of the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Yazeed Sawalha · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 14 · Phase 3 3
First in 2011; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 45 across 1,499 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 44 across the 26 interventional studies. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 26 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pharmacyclics LLC., one of the names counted as AbbVie. Under that name alone:
Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie: 2 open now, 5 under way, none of them phase 3. Of 7 finished, 4 (57%) have results posted.
Among the 12 studies in Lymphoma, Large B-Cell, Diffuse by AbbVie, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2014, is one of 3 in phase 1/2, and was the 3rd registered.
AbbVie’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2008.
5 of the studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT01479842Kami Maddocks, MDRituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | 2026-12-01 |
| NCT03960840Novartis PharmaceuticalsPhase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL | 2027-06-30 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
| NCT06536049Yazeed SawalhaEpcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 26 studies testing ibrutinib in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among AbbVie’s 12 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for transplant.
Phase 1b: In the dose escalation portion of the study, various cohorts with escalating doses of lenalidomide may be explored, using the 3+3+3 principle for dose determination.
Phase 2: This will be conducted as an international, multicenter, open-label study. Eligible subjects will receive ibrutinib, lenalidomide and rituximab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ibrutinib 560 mg administered orally (PO) once daily (QD) beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered intravenously (IV) on Day 1 of each 28-day cycle for 6 cycles.
Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab
De-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab
Re-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab
Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab
Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab
Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab
Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m\^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
Drug: Ibrutinib · Drug: Lenalidomide · Drug: Rituximab
Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The dose levels of lenalidomide were explored, and dose escalation of lenalidomide followed the 3+3+3 dose escalation schema. A Dose Level Review Committee evaluated safety data following completion of each dose observation period of the Phase 1b portion.
Time frame: Estimated median time on study in Phase 1b was 59.6 months.
Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuations Due to TEAEs
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \> 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death.
Time frame: From first dose of study drug up to 30 days after last dose of study drug. Phase 1b median duration of ibrutinib exposure was 4.4 months; median duration of lenalidomide exposure was 4.4 months; median total number of doses of rituximab received was 4.0.
Phase 2: Overall Response Rate (ORR)
The ORR was defined as the percentage of participants who achieve either a partial response (PR) or complete response (CR), according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014), as assessed by the investigator in response-evaluable population. The 95% confidence interval (CI) was calculated using the exact method.
Time frame: Estimated median time on study in Phase 2 was 35.0 months.
Phase 1b: ORR
The ORR was defined as the percentage of participants who achieve either a PR or CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease and PR=regression of measurable disease and no new sites. The 95% CI was calculated using the exact method.
Time frame: Estimated median time on study in Phase 1b was 59.6 months.
Phase 1b: Complete Response (CR) Rate
The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease, as assessed by the Investigator.
Time frame: Estimated median time on Phase 1b study was 59.6 months.
Phase 2: CR Rate
The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (see Cheson, 2014 for detailed criteria) in response-evaluable population, as assessed by the Investigator.
Time frame: Estimated median time on study in Phase 2 was 35.0 months.
Phase 2: Duration of Response (DOR)
DOR is defined as the time from the date of the first documented response (CR or PR) to the first documented evidence of disease progression (PD) according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause. For participants who had achieved an overall response but did not die or progress at the time of analysis, DOR was censored on the date of the last adequate post-baseline disease assessment, or on the date of the first occurrence of response (CR or PR) if there was no disease assessment afterwards. 2-sided 95% CI is estimated by Kaplan-Meier method.
Time frame: Estimated median time on study in Phase 2 was 35.0 months.
Phase 2: Progression Free Survival (PFS)
PFS is defined as the time from the date of the first dose of study drug to confirmed PD according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause, whichever occurred first. For participants without disease progression or death, PFS data was censored at the date of the last tumor assessment. 2 sided 95% CI is estimated by Kaplan-Meier method.
Time frame: Estimated median time on study in Phase 2 was 35.0 months.
Phase 2: Overall Survival (OS)
OS is defined as the time from the date of the first dose of study drug to the date of death due to any cause. For participants not known to have died at or prior to the database lock date, OS data was censored at the date last known alive. Participants who withdrew consent prior to study closure were censored on the date of the consent withdrawal. 2-sided 95% CI was estimated by Kaplan-Meier method.
Time frame: Estimated median time on study in Phase 2 was 35.0 months.
Phase 2: Number of Participants With TEAEs, Serious TEAEs, and Discontinuations Due to TEAEs
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \> 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death.
Time frame: From first dose of study drug up to 30 days after last dose of study drug. Phase 2 median duration of ibrutinib exposure was 4.9 months; median duration of lenalidomide exposure was 4.7 months; median total number of doses of rituximab received was 5.0.
All participants had relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In the Phase 1b portion of the study, all subtypes of DLBCL and participants with transformed disease were enrolled. In the Phase 2 portion of the study, only participants with non-germinal-center B-cell-like (non-GCB) DLBCL were enrolled.
| Milestone | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg |
|---|---|---|---|---|---|---|---|
| Started | 12 | 7 | 9 | 9 | 8 | 55 | 34 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 12 | 7 | 9 | 9 | 8 | 55 | 34 |
| Withdrew: Death | 6 | 7 | 5 | 6 | 4 | 32 | 22 |
| Withdrew: Study closure by sponsor | 3 | 0 | 2 | 2 | 2 | 12 | 4 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 | 1 | 1 | 1 | 3 | 0 |
| Withdrew: Other, not specified | 0 | 0 | 1 | 0 | 1 | 7 | 8 |
The dose levels of lenalidomide were explored, and dose escalation of lenalidomide followed the 3+3+3 dose escalation schema. A Dose Level Review Committee evaluated safety data following completion of each dose observation period of the Phase 1b portion.
| mg | All Phase 1b Participants |
|---|---|
| Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | 20 |
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \> 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death.
| Participants | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) |
|---|---|---|---|---|---|
| Any TEAE | 12 | 7 | 9 | 9 | 8 |
| Any Grade >=3 TEAE | 11 | 6 | 9 | 9 | 7 |
| Any Study Drug-Related TEAE | 12 | 5 | 9 | 8 | 8 |
| Any Grade >=3 Study Drug-Related TEAE | 10 | 3 | 8 | 7 | 7 |
| Any Ibrutinib-Related TEAE | 12 | 5 | 9 | 8 | 8 |
| Any Grade >=3 Ibrutinib-Related TEAE | 10 | 3 | 7 | 7 | 6 |
| Any Lenalidomide-Related TEAE | 12 | 5 | 9 | 8 | 8 |
| Any Grade >=3 Lenalidomide-Related TEAE | 9 | 3 | 8 | 7 | 6 |
| Any Rituximab-Related TEAE | 6 | 4 | 7 | 6 | 7 |
| Any Grade >= 3 Rituximab-Related TEAE | 1 | 2 | 7 | 5 | 3 |
| Any TEAE Leading to Dose Reduction of Any Study Drug | 4 | 0 | 4 | 4 | 5 |
| Any TEAE Leading to Dose Reduction of Ibrutinib | 3 | 0 | 4 | 3 | 3 |
| Any TEAE Leading to Dose Reduction of Lenalidomide | 2 | 0 | 3 | 4 | 4 |
| Any TEAE Leading to Dose Delay of Any Study Drug | 6 | 4 | 7 | 8 | 8 |
| Any TEAE Leading to Dose Delay of Ibrutinib | 6 | 4 | 7 | 8 | 8 |
| Any TEAE Leading to Dose Delay of Lenalidomide | 6 | 3 | 7 | 7 | 8 |
| Any TEAE Leading to Dose Delay of Rituximab | 4 | 1 | 6 | 4 | 4 |
| Any TEAE Leading to Discontinuation of Any Study Drug | 4 | 2 | 3 | 2 | 1 |
| Any TEAE Leading to Discontinuation of Ibrutinib Dose | 4 | 2 | 3 | 2 | 1 |
| Any TEAE Leading to Discontinuation of Lenalidomide Dose | 4 | 2 | 3 | 2 | 1 |
| Any TEAE Leading to Discontinuation of Rituximab Dose | 3 | 2 | 3 | 2 | 1 |
| Any Serious TEAE | 4 | 6 | 7 | 5 | 6 |
| Any Grade >=3 Serious TEAE | 4 | 6 | 6 | 4 | 6 |
| Any Treatment-Related Serious TEAE | 0 | 2 | 4 | 2 | 3 |
| Any Ibrutinib-Related Serious TEAE | 0 | 2 | 4 | 2 | 3 |
| Any Lenalidomide-Related Serious TEAE | 0 | 2 | 4 | 2 | 3 |
| Any Rituximab-Related Serious TEAE | 0 | 2 | 2 | 1 | 0 |
| Any Fatal TEAE | 0 | 2 | 2 | 1 | 1 |
The ORR was defined as the percentage of participants who achieve either a partial response (PR) or complete response (CR), according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014), as assessed by the investigator in response-evaluable population. The 95% confidence interval (CI) was calculated using the exact method.
| percentage of participants | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg | Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg |
|---|---|---|---|
| Phase 2: Overall Response Rate (ORR) | 52.8 (38.6 to 66.7) | 43.8 (26.4 to 62.3) | 49.4 (38.4 to 60.5) |
The ORR was defined as the percentage of participants who achieve either a PR or CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease and PR=regression of measurable disease and no new sites. The 95% CI was calculated using the exact method.
| percentage of participants | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | Phase 1b Total: Enrolled at Lenalidomide Dose 10 to 25 mg (All Dose Levels) |
|---|---|---|---|---|---|---|
| Phase 1b: ORR | 44.4 (13.7 to 78.8) | 0 (0 to 41.0) | 71.4 (29.0 to 96.3) | 22.2 (2.8 to 60.0) | 75.0 (34.9 to 96.8) | 42.5 (27.0 to 59.1) |
The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease, as assessed by the Investigator.
| percentage of participants | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | Phase 1b Total: Enrolled at Lenalidomide Dose 10 to 25 mg (All Dose Levels) |
|---|---|---|---|---|---|---|
| Phase 1b: Complete Response (CR) Rate | 33.3 | 0 | 42.9 | 11.1 | 50.0 | 27.5 |
The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (see Cheson, 2014 for detailed criteria) in response-evaluable population, as assessed by the Investigator.
| percentage of participants | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg | Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg |
|---|---|---|---|
| Phase 2: CR Rate | 32.1 | 21.9 | 28.2 |
DOR is defined as the time from the date of the first documented response (CR or PR) to the first documented evidence of disease progression (PD) according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause. For participants who had achieved an overall response but did not die or progress at the time of analysis, DOR was censored on the date of the last adequate post-baseline disease assessment, or on the date of the first occurrence of response (CR or PR) if there was no disease assessment afterwards. 2-sided 95% CI is estimated by Kaplan-Meier method.
| months | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg | Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg |
|---|---|---|---|
| Phase 2: Duration of Response (DOR) | 38.3 (3.7 to NA) | 28.6 (2.8 to 28.6) | 38.3 (9.5 to NA) |
PFS is defined as the time from the date of the first dose of study drug to confirmed PD according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause, whichever occurred first. For participants without disease progression or death, PFS data was censored at the date of the last tumor assessment. 2 sided 95% CI is estimated by Kaplan-Meier method.
| months | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg | Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg |
|---|---|---|---|
| Phase 2: Progression Free Survival (PFS) | 5.4 (3.4 to 11.3) | 4.7 (2.6 to 24.8) | 5.4 (3.4 to 6.3) |
OS is defined as the time from the date of the first dose of study drug to the date of death due to any cause. For participants not known to have died at or prior to the database lock date, OS data was censored at the date last known alive. Participants who withdrew consent prior to study closure were censored on the date of the consent withdrawal. 2-sided 95% CI was estimated by Kaplan-Meier method.
| months | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg | Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg |
|---|---|---|---|
| Phase 2: Overall Survival (OS) | 14.7 (9.7 to 32.8) | 11.6 (5.7 to NA) | 14.2 (9.7 to 28.1) |
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization \> 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death.
| Participants | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg | Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg |
|---|---|---|---|
| Any TEAE | 55 | 34 | 89 |
| Any Grade >=3 TEAE | 51 | 30 | 81 |
| Any Study Drug-Related TEAE | 52 | 33 | 85 |
| Any Grade >=3 Study Drug-Related TEAE | 41 | 25 | 66 |
| Any Ibrutinib-Related TEAE | 50 | 32 | 82 |
| Any Grade >=3 Ibrutinib-Related TEAE | 36 | 24 | 60 |
| Any Lenalidomide-Related TEAE | 51 | 32 | 83 |
| Any Grade >=3 Lenalidomide-Related TEAE | 40 | 25 | 65 |
| Any Rituximab-Related TEAE | 37 | 25 | 62 |
| Any Grade >= 3 Rituximab-Related TEAE | 18 | 13 | 31 |
| Any TEAE Leading to Dose Reduction of Any Study Drug | 23 | 14 | 37 |
| Any TEAE Leading to Dose Reduction of Ibrutinib | 12 | 9 | 21 |
| Any TEAE Leading to Dose Reduction of Lenalidomide | 21 | 14 | 35 |
| Any TEAE Leading to Dose Delay of Any Study Drug | 40 | 29 | 69 |
| Any TEAE Leading to Dose Delay of Ibrutinib | 38 | 28 | 66 |
| Any TEAE Leading to Dose Delay of Lenalidomide | 37 | 26 | 63 |
| Any TEAE Leading to Dose Delay of Rituximab | 10 | 6 | 16 |
| Any TEAE Leading to Discontinuation of Any Study Drug | 11 | 7 | 18 |
| Any TEAE Leading to Discontinuation of Ibrutinib Dose | 11 | 5 | 16 |
| Any TEAE Leading to Discontinuation of Lenalidomide Dose | 11 | 7 | 18 |
| Any TEAE Leading to Discontinuation of Rituximab Dose | 6 | 4 | 10 |
| Any Serious TEAE | 32 | 25 | 57 |
| Any Grade >=3 Serious TEAE | 29 | 21 | 50 |
| Any Treatment-Related Serious TEAE | 16 | 12 | 28 |
| Any Ibrutinib-Related Serious TEAE | 14 | 12 | 26 |
| Any Lenalidomide-Related Serious TEAE | 16 | 10 | 26 |
| Any Rituximab-Related Serious TEAE | 4 | 5 | 9 |
| Any Fatal TEAE | 8 | 4 | 12 |
Collected over All Cause Mortality Time Frame: Estimated median time on study in Phase 1b was 59.6 months. Estimated median time on study in Phase 2 was 35.0 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | 7/12 (58.3%) | 4/12 (33.3%) | 12/12 (100%) |
| Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | 7/7 (100%) | 6/7 (85.7%) | 7/7 (100%) |
| Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | 5/9 (55.6%) | 7/9 (77.8%) | 9/9 (100%) |
| Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | 7/9 (77.8%) | 5/9 (55.6%) | 9/9 (100%) |
| Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | 5/8 (62.5%) | 6/8 (75%) | 8/8 (100%) |
| Phase 2: Enrolled at Lenalidomide Dose 20 mg | 33/55 (60%) | 32/55 (58.2%) | 54/55 (98.2%) |
| Phase 2: Enrolled at Lenalidomide Dose 25 mg | 22/34 (64.7%) | 25/34 (73.5%) | 34/34 (100%) |
| Event | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg |
|---|---|---|---|---|---|---|---|
| DIFFUSE LARGE B-CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/12 | 2/7 | 1/9 | 2/9 | 1/8 | 5/55 | 3/34 |
| CELLULITISInfections and infestations | 0/12 | 1/7 | 1/9 | 0/9 | 2/8 | 2/55 | 1/34 |
| ANAEMIABlood and lymphatic system disorders | 0/12 | 0/7 | 2/9 | 0/9 | 0/8 | 1/55 | 0/34 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 0/12 | 0/7 | 0/9 | 2/9 | 1/8 | 0/55 | 2/34 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/12 | 0/7 | 1/9 | 2/9 | 1/8 | 1/55 | 1/34 |
| PANCYTOPENIABlood and lymphatic system disorders | 0/12 | 1/7 | 0/9 | 0/9 | 0/8 | 0/55 | 0/34 |
| BILE DUCT STENOSISHepatobiliary disorders | 0/12 | 1/7 | 0/9 | 0/9 | 0/8 | 0/55 | 0/34 |
| FOLLICULITISInfections and infestations | 0/12 | 1/7 | 0/9 | 0/9 | 0/8 | 0/55 | 0/34 |
| PNEUMONIAInfections and infestations | 0/12 | 1/7 | 1/9 | 0/9 | 0/8 | 3/55 | 2/34 |
| SALMONELLA BACTERAEMIAInfections and infestations | 0/12 | 1/7 | 0/9 | 0/9 | 0/8 | 0/55 | 0/34 |
| Event | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg |
|---|---|---|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 9/12 | 3/7 | 3/9 | 4/9 | 7/8 | 32/55 | 13/34 |
| NEUTROPENIABlood and lymphatic system disorders | 5/12 | 0/7 | 6/9 | 3/9 | 5/8 | 25/55 | 14/34 |
| NAUSEAGastrointestinal disorders | 7/12 | 3/7 | 3/9 | 3/9 | 4/8 | 17/55 | 9/34 |
| FATIGUEGeneral disorders | 6/12 | 3/7 | 5/9 | 2/9 | 3/8 | 22/55 | 16/34 |
| RASH MACULO-PAPULARSkin and subcutaneous tissue disorders | 2/12 | 1/7 | 5/9 | 3/9 | 2/8 | 15/55 | 12/34 |
| OEDEMA PERIPHERALGeneral disorders | 2/12 | 1/7 | 3/9 | 3/9 | 4/8 | 21/55 | 8/34 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 4/12 | 2/7 | 4/9 | 4/9 | 3/8 | 11/55 | 10/34 |
| CONSTIPATIONGastrointestinal disorders | 5/12 | 2/7 | 4/9 | 4/9 | 3/8 | 11/55 | 10/34 |
| DECREASED APPETITEMetabolism and nutrition disorders | 2/12 | 1/7 | 4/9 | 2/9 | 2/8 | 8/55 | 5/34 |
| PETECHIAESkin and subcutaneous tissue disorders | 1/12 | 0/7 | 0/9 | 4/9 | 2/8 | 5/55 | 2/34 |
| Age, Continuous(years) | Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | Phase 1: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | Phase 1: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | Phase 1: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 66.3 ± 13.13 | 58.4 ± 7.63 | 65.3 ± 13.44 | 66.0 ± 8.63 | 62.9 ± 14.23 | 63.1 ± 11.75 | 64.9 ± 12.52 | 63.9 ± 11.88 |
| Sex: Female, Male(Participants) | Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | Phase 1: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | Phase 1: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | Phase 1: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 5 | 5 | 3 | 23 | 14 | 57 |
| Male | 8 | 4 | 4 | 4 | 5 | 32 | 20 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | Phase 1: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | Phase 1: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | Phase 1: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 1 | 0 | 0 | 0 | 5 | 10 |
| Not Hispanic or Latino | 11 | 4 | 8 | 9 | 8 | 55 | 29 | 124 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) | Phase 1: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) | Phase 1: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) | Phase 1: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) | Phase 1: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) | Phase 2: Enrolled at Lenalidomide Dose 20 mg | Phase 2: Enrolled at Lenalidomide Dose 25 mg | Total |
|---|---|---|---|---|---|---|---|---|
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 |
| Black or African American | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 7 |
| White | 11 | 5 | 8 | 9 | 7 | 51 | 30 | 121 |
| Multiple Races | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Declined to Answer/Unknown | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Requests for access to individual participant data from clinical studies conducted by Pharmacyclics LLC, an AbbVie Company, can be submitted through Yale Open Data Access (YODA) Project site at the following link.
Data sharing details ↗ · yoda.yale.edu
Ran from Mar 2014 to primary completion in Dec 2020, 81 months.
Results were first posted in Feb 2022, 1 year 1 month after primary completion.
Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 81 months is close to that.
Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ibrutinib · Lenalidomide · Rituximab
Lymphoma, Large B-Cell, Diffuse →